MA55477A - Inhibiteurs de hpk1 - Google Patents
Inhibiteurs de hpk1Info
- Publication number
- MA55477A MA55477A MA055477A MA55477A MA55477A MA 55477 A MA55477 A MA 55477A MA 055477 A MA055477 A MA 055477A MA 55477 A MA55477 A MA 55477A MA 55477 A MA55477 A MA 55477A
- Authority
- MA
- Morocco
- Prior art keywords
- hpk1 inhibitors
- hpk1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823708P | 2019-03-26 | 2019-03-26 | |
| EP19167820 | 2019-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55477A true MA55477A (fr) | 2022-02-09 |
Family
ID=69845447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055477A MA55477A (fr) | 2019-03-26 | 2020-03-24 | Inhibiteurs de hpk1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12492194B2 (fr) |
| EP (1) | EP3947366B1 (fr) |
| AU (1) | AU2020249409A1 (fr) |
| CA (1) | CA3129768A1 (fr) |
| ES (1) | ES3035145T3 (fr) |
| MA (1) | MA55477A (fr) |
| TW (1) | TW202102488A (fr) |
| WO (1) | WO2020193511A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| EP3972695A1 (fr) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
| CN114437058A (zh) * | 2020-10-30 | 2022-05-06 | 珠海宇繁生物科技有限责任公司 | 氘代hpk1激酶抑制剂及其制备方法和应用 |
| WO2022184152A1 (fr) * | 2021-03-03 | 2022-09-09 | 劲方医药科技(上海)有限公司 | Composé hétérocyclique à six chaînons substitué par un cycle condensé, son procédé de préparation et son utilisation |
| JP2024517771A (ja) * | 2021-04-30 | 2024-04-23 | オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） | 造血前駆キナーゼ１（ｈｐｋ１）の阻害剤としての置換アミノアザヘテロアリール化合物 |
| US20240425479A1 (en) * | 2021-04-30 | 2024-12-26 | Ontario Institute For Cancer Research (Oicr) | Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
| TW202321239A (zh) | 2021-07-20 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺 |
| TW202440581A (zh) | 2022-12-16 | 2024-10-16 | 中國大陸商杭州中美華東製藥有限公司 | Protac嵌合化合物及其製備方法和用途 |
| CN120058709A (zh) * | 2023-11-28 | 2025-05-30 | 杭州和正医药有限公司 | 一种多芳基类衍生物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115653B2 (en) * | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| CN107206088A (zh) | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
| MA42456B1 (fr) | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018049214A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| WO2018081531A2 (fr) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Méthodess d'activation de lymphocytes t humains |
| WO2018102366A1 (fr) | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
| CN110402248B (zh) | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| EP3601259B1 (fr) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
| AU2018244935A1 (en) | 2017-03-30 | 2019-08-15 | F. Hoffmann-La Roche Ag | Naphthyridines as inhibitors of HPK1 |
| AU2018272986A1 (en) | 2017-05-26 | 2019-12-12 | Ichnos Sciences SA | Novel inhibitors of MAP4K1 |
| EP3638669A1 (fr) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués |
| WO2018228925A1 (fr) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués |
| EP3638670B1 (fr) | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Dérivés de pyrrolopyridine substitués utilisés en tant que modulateurs de map4k1 pour le traitement de maladies cancéreuses |
| US10722495B2 (en) * | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
-
2020
- 2020-03-24 US US17/442,650 patent/US12492194B2/en active Active
- 2020-03-24 ES ES20711972T patent/ES3035145T3/es active Active
- 2020-03-24 EP EP20711972.8A patent/EP3947366B1/fr active Active
- 2020-03-24 CA CA3129768A patent/CA3129768A1/fr active Pending
- 2020-03-24 WO PCT/EP2020/058081 patent/WO2020193511A1/fr not_active Ceased
- 2020-03-24 AU AU2020249409A patent/AU2020249409A1/en not_active Abandoned
- 2020-03-24 TW TW109109735A patent/TW202102488A/zh unknown
- 2020-03-24 MA MA055477A patent/MA55477A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3129768A1 (fr) | 2020-10-01 |
| US12492194B2 (en) | 2025-12-09 |
| AU2020249409A1 (en) | 2021-09-30 |
| EP3947366A1 (fr) | 2022-02-09 |
| ES3035145T3 (en) | 2025-08-29 |
| WO2020193511A1 (fr) | 2020-10-01 |
| US20220177458A1 (en) | 2022-06-09 |
| TW202102488A (zh) | 2021-01-16 |
| EP3947366C0 (fr) | 2025-05-21 |
| EP3947366B1 (fr) | 2025-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| IL283639A (en) | Kif18a inhibitors | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| IL282535A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| IL289612A (en) | Hpk1 inhibitors and uses thereof | |
| MA55477A (fr) | Inhibiteurs de hpk1 | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3856176A4 (fr) | Inhibiteurs de vap-1 | |
| EP3966213A4 (fr) | Inhibiteurs de cdk | |
| EP3761992A4 (fr) | Inhibiteurs d'arginase | |
| EP3980011C0 (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA55478A (fr) | Inhibiteurs bicycliques de hpk1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3938358A4 (fr) | Inhibiteurs de rad51 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3930851A4 (fr) | Polythérapies | |
| EP3856194A4 (fr) | Inhibiteurs de vap-1 | |
| EP3742771C0 (fr) | Notification m2m sm-sr à sm-dp | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| EP3912517C0 (fr) | Cadre |